Skip to main content
Alligator Bioscience logo

Alligator Bioscience — Investor Relations & Filings

Ticker · ATORX ISIN · SE0024173637 LEI · 549300E15VI0MB7LXV19 ST Manufacturing
Open in API
Filings indexed 610 across all filing types
Latest filing 2024-12-02 Capital/Financing Update
Country SE Sweden
Listing ST ATORX

About Alligator Bioscience

https://alligatorbioscience.se/en/

Alligator Bioscience is a clinical-stage biotechnology company that develops tumor-directed immuno-oncology antibody drugs. The company's core strategy is to activate the patient's own immune system to fight cancer. It utilizes a proprietary technology platform for the discovery and development of novel antibody-based pharmaceuticals. The development pipeline features several drug candidates, including its lead asset mitazalimab, a CD40 agonist. The company specializes in creating therapeutics that are designed to be effective against various forms of cancer.

Recent filings

Filing Released Lang Actions
Alligator Bioscience genomför en företrädesemission av units om cirka 280 MSEK samt upptar brygglån
Capital/Financing Update Classification · 1% confidence The document is a press release from Alligator Bioscience announcing a rights issue (företrädesemission) of units (shares and warrants) to raise approximately 280 MSEK, along with bridge financing and organizational restructuring. It details the terms, background, and purpose of the capital raise. This falls under the category of capital and financing updates.
2024-12-02 Swedish
Alligator Bioscience carries out a rights issue of units of approximately SEK 280 million and raises bridge loans
Capital/Financing Update Classification · 1% confidence The document is a press release announcing a significant corporate financing event: a 'Rights Issue of Units of approximately SEK 280 million' involving the issuance of ordinary shares and warrants. This activity directly relates to raising capital and changing the capital structure. Based on the provided definitions, the most appropriate classification is 'Capital/Financing Update' (CAP). It is not a full Annual Report (10-K), an Earnings Release (ER), or a simple Dividend Notice (DIV). Since it is a detailed announcement about the financing terms, it is the primary document, not just a Report Publication Announcement (RPA).
2024-12-02 English
Alligator skärper fokus på mitazalimab och planerar omstrukturering för att förstärka den långsiktiga värdeskapande förmågan
Regulatory Filings Classification · 1% confidence The document is a press release from Alligator Bioscience AB dated December 2, 2024, announcing a strategic refocusing on their lead candidate, mitazalimab, and a planned workforce restructuring resulting in cost savings. It also mentions plans for a rights issue in Q1 2025 and upcoming 24-month follow-up data. The text explicitly states, "Denna information är sådan information som Alligator Bioscience är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning." (This information is information that Alligator Bioscience is obliged to disclose pursuant to the EU Market Abuse Regulation.) Furthermore, the document ends with a section titled "Bifogade filer" (Attached files) which links to a PDF of the announcement itself. This structure—a brief announcement detailing material corporate actions (restructuring, financing plans, strategic focus) and referencing regulatory obligation, often accompanied by the full document attached—is characteristic of a general regulatory disclosure or press release that doesn't fit a more specific financial report category (like 10-K, IR, or ER). Since it is a broad announcement mandated by market rules and doesn't fit ER (Earnings Release), IR (Interim Report), or CAP (Capital/Financing Update) as the primary type (though it mentions financing), the most appropriate general regulatory filing category is RNS (Regulatory Filings), which serves as the fallback for such mandatory disclosures not covered elsewhere, especially when the content is a mix of operational and financial strategy updates.
2024-12-02 Swedish
Alligator announces sale of future financial commitments for two bispecific antibodies to Orion Corporation
Capital/Financing Update Classification · 1% confidence The document announces a specific corporate transaction: the sale of future financial commitments related to two antibodies to Orion Corporation. This is a material event disclosure. The text mentions it is an announcement, provides key financial details (€3.5 million), and concludes with a statement about compliance with the EU Market Abuse Regulation and the publication time. Crucially, at the end, it lists an 'Attachment' which is a link to a PDF document detailing the announcement. Given the short length (under 5,000 characters) and the nature of announcing a report/filing availability (even if the announcement itself is the primary content here), this strongly suggests a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). Since the content is a specific, material corporate action announcement, and not a general regulatory filing fallback, RPA is more appropriate if the document is primarily the announcement linking to the full details, or if it were a standard earnings release (ER) or capital update (CAP). This transaction is a form of capital/financing activity (divestiture of future revenue streams) but is presented as a formal press release/announcement. Given the structure—a press release announcing a specific deal and linking to the full document—it fits best under the general Regulatory Filings (RNS) category if it doesn't fit a more specific transactional category. However, since it details a financing/asset sale, 'CAP' (Capital/Financing Update) is a strong candidate. Since it is a specific transaction announcement, and not a general report announcement, I will classify it as CAP, as it directly relates to the company's financing/asset structure, although RNS is also plausible for non-standard announcements. Given the focus on a transaction that yields non-dilutive income, CAP is the most specific fit among the transactional categories.
2024-11-19 English
Alligator säljer rätten till framtida finansiella åtaganden för två bispecifika antikroppar till Orion Corporation
Regulatory Filings Classification · 1% confidence The document is a press release from Alligator Bioscience announcing a specific corporate transaction: selling the rights to future financial commitments related to two antibodies to Orion Corporation for 3.5 MEUR. It includes key financial details, management commentary, and is explicitly dated and marked as information required to be made public under EU market abuse regulation. This type of announcement, detailing a significant corporate transaction (asset sale/licensing deal) that impacts future revenue streams and strategy, fits best under Capital/Financing Update (CAP) or potentially Regulatory Filings (RNS) if no other category is suitable. Since it details a financing/transaction event (selling future payments), CAP is a strong candidate. However, given the nature of the announcement (a specific corporate action/deal disclosure), and the fact that it is a general press release format, it is often categorized as a general Regulatory Filing (RNS) if the specific transaction type isn't explicitly covered by other codes like M&A (TAR). Since this is a sale of future revenue streams/rights, it is a significant corporate event disclosure. Given the options, and that it is not a standard earnings release (ER), interim report (IR), or formal statutory filing (10-K), RNS (Regulatory Filings - general regulatory announcements/fallback) is the most appropriate general classification for a non-standard, material press release disclosure, although CAP is also plausible. I will select RNS as the primary fallback for material, non-standard corporate news releases.
2024-11-19 Swedish
Nomination Committee appointed in respect of AGM 2025 in Alligator Bioscience AB
AGM Information Classification · 1% confidence The document explicitly discusses the appointment of the Nomination Committee in preparation for the 'Annual General Meeting (AGM) on May 7, 2025'. It details the composition, rights, and tasks of this committee, which is a core component of corporate governance related to shareholder meetings. This content directly relates to the procedures and materials surrounding the AGM. While it is an announcement, the subject matter is specific to AGM preparation rather than a general regulatory filing (RNS) or a general governance report (CGR). Therefore, the most appropriate classification is AGM Information (AGM-R).
2024-10-31 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.